Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Denmark-Based Xellia Pharmaceuticals To Open Manufacturing Center In Bedford, Ohio

11/25/2015
Denmark-based Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has acquired manufacturing facilities in Bedford, Ohio. The facilities were bought from a wholly owned subsidiary of Hikma Pharmaceuticals.

Under the terms of the agreement, Xellia has acquired substantial parts of the site including several new manufacturing units for sterile injectables which are not currently operational. Hikma will retain the remaining facilities including the Quality and Development Center which has been operated by its subsidiary, West-Ward Injectables, Inc. since it acquired the site in 2014.

Carl-Åke Carlsson, CEO, Xellia said: “The US is a very important market for us, and as a region with a strong manufacturing heritage and a uniquely skilled and specialized workforce, Bedford, Ohio is an ideal location to expand our manufacturing capabilities. Together with our production site and new US headquarters in Raleigh, North Carolina, Xellia is in a great place to help make critical anti-infectives available to the patients that need them. We are looking forward to being co-located at the Bedford site with Hikma and to continue to work closely with them in the future.”

Xellia intends to recruit around 170 new employees across a range of departments including; manufacturing, supply chain, distribution, quality, engineering, human resources and finance at the Bedford site over an initial twenty-four month period.

Company officials said Xellia plans to invest significantly in the facilities to resume manufacturing in the new units at the site and in the establishment and training of a new organization to operate the plant. The Company will work closely with the US Food and Drug Administration to ensure a timely and controlled start-up at the facility.

Xellia plans to begin commercial production at the site within 24 months. The facility will operate alongside the Company’s existing sterile injectables production plant in Raleigh. The Bedford site significantly increases Xellia’s production capacity for sterile injectable products in the US, ability to meet the growing needs of its US customers and enables future pipeline expansion.

Exclusive Research